Literature DB >> 2965716

Emergency coronary artery bypass surgery preserves global and regional left ventricular function after intravenous tissue plasminogen activator therapy for acute myocardial infarction.

D J Kereiakes1, E J Topol, B S George, C W Abbottsmith, R S Stack, R J Candela, W W O'Neill, L H Martin, R M Califf.   

Abstract

Emergency coronary bypass surgery was performed in 24 (6.2%) of 386 consecutive patients enrolled in the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Multicenter Trial. Intravenous tissue plasminogen activator was administered 2.6 +/- 0.7 h and bypass surgery was performed 7.3 +/- 1.9 h after the onset of infarction. Infarct artery patency was achieved in 21 (88%) of the 24 patients (pharmacologically in 18 or mechanically with coronary angioplasty in 3) in the catheterization laboratory before bypass surgery. The indication for surgery was left main or equivalent coronary artery disease in 7 patients, coronary anatomy unsuitable for angioplasty in 4 patients and unsuccessful coronary angioplasty in 13 patients. A coronary perfusion catheter was inserted before surgery in 11 of 13 patients with unsuccessful angioplasty. All three deaths occurred postoperatively in patients with preoperative cardiogenic shock. Three patients required surgical reexploration for postoperative hemorrhage. Comparison of preoperative and predischarge contrast left ventriculograms demonstrated significant preservation of global (left ventricular ejection fraction 49 +/- 6 to 56 +/- 6%; p = 0.008) and regional (standard deviation/chord -2.6 +/- 0.5 to -1.5 +/- 1.1; p = 0.001) left ventricular function. Emergency coronary bypass surgery can be performed with a low morbidity and mortality in patients treated with intravenous tissue plasminogen activator therapy for acute myocardial infarction. Such therapy is associated with significant preservation of global and regional (infarct zone) left ventricular function.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2965716     DOI: 10.1016/s0735-1097(98)90043-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  4 in total

1.  Coronary revascularization rather than cardiac transplantation for chronic ischemic cardiomyopathy.

Authors:  I L Kron; T L Flanagan; L H Blackbourne; R A Schroeder; S P Nolan
Journal:  Ann Surg       Date:  1989-09       Impact factor: 12.969

2.  Does the additive risk of mitral valve repair in patients with ischemic cardiomyopathy prohibit surgical intervention?

Authors:  J J Gangemi; C G Tribble; S D Ross; J A McPherson; J A Kern; I L Kron
Journal:  Ann Surg       Date:  2000-05       Impact factor: 12.969

Review 3.  Revascularization therapy for coronary artery disease. Coronary artery bypass grafting versus percutaneous transluminal coronary angioplasty.

Authors:  J M Wilson; J J Ferguson
Journal:  Tex Heart Inst J       Date:  1995

4.  After thrombolytic therapy: angiography, angioplasty, or surgery?

Authors:  M L Stadius
Journal:  Tex Heart Inst J       Date:  1990
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.